Stanford University
Showing 61-70 of 2,304 Results
-
Christine Anastasiou, MD, MAS
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
BioDr. Anastasiou is a board-certified, fellowship-trained rheumatologist with the Stanford Health Care Immunology and Rheumatology Clinic. She is also a clinical assistant professor in the Department of Medicine, Division of Immunology and Rheumatology at Stanford University School of Medicine.
Dr. Anastasiou specializes in diagnosing and treating patients with rheumatic diseases. She has a special interest in ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, and idiopathic inflammatory myopathies.
Her scholarly work includes epidemiologic studies and clinical trials focused on improving safety and health outcomes for people with chronic rheumatic diseases. Dr. Anastasiou has served as an investigator and collaborator for clinical trials of new therapies to treat rheumatic disease. She is actively involved in medical education through developing and leading patient, medical student, resident, and fellow educational programs.
Dr. Anastasiou is a member of the American College of Rheumatology (ACR). She has published her research in peer-reviewed journals, including Arthritis Care & Research and Lupus Science & Medicine. She has delivered lectures and presentations across the country and abroad on various topics related to rheumatology. -
Chad Anderson
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioChad Anderson is a Physician Assistant at Stanford ValleyCare and a Clinical Assistant Professor with the Stanford School of Medicine MSPA program. He is the Assistant Director of PA education at ValleyCare. He is dual credentialed as a Family Nurse Practitioner and a Physician Assistant. He completed his FNP/PA training at the Stanford School of Medicine and his graduate studies at A.T. Still University – Arizona School of Health Sciences. He is passionate about improving our patients hospital experience as well as educating our future providers.
-
Jason Andrews
Professor of Medicine (Infectious Diseases) and, by courtesy, of Epidemology
Current Research and Scholarly InterestsOur laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.
-
Justin P. Annes M.D., Ph.D.
Associate Professor of Medicine (Endocrinology)
On Partial Leave from 05/01/2024 To 02/28/2025Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
DIABETES
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.
